Name | 4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]-2-(1,1,2,2,2-pentadeuterioethoxy)benzoic acid |
---|---|
Synonyms |
[2H5]-Repaglinide
Repaglinide-ethyl-d5 |
Description | Repaglinide D5 (AG-EE 623ZW D5) is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1]. |
---|---|
Related Catalog | |
In Vitro | Repaglinide reduces postprandial glucose levels by enhancing the early phase of insulin secretion and increasing the total amount of insulin secreted[1]. |
References |
Molecular Formula | C27H31D5N2O4 |
---|---|
Molecular Weight | 457.61700 |
Exact Mass | 457.29900 |
PSA | 82.36000 |
LogP | 6.12520 |
Storage condition | -20°C |